MXRA5 Is a Novel Immune-Related Biomarker That Predicts Poor Prognosis in Glioma.

Background: Glioma is the most common primary intracranial tumor and is associated with poor prognosis. Identifying effective biomarkers for glioma is particularly important. MXRA5, a secreted glycoprotein, is involved in cell adhesion and extracellular matrix remodeling and has been reported to be expressed in many cancers.